Home | Welcome to Contract Pharma   
Last Updated Friday, August 22 2014
Print RSS Feed

Financial Report: Charles River Laboratories



By Kristin Brooks



Published February 12, 2014
Charles River Laboratories
 
4Q Revenues: $289.2 million (+3%)

4Q Earnings: $19.1 million (+4%)

FY Revenues: $1.2 billion (+3%)

FY Earnings: $102.8 million (+6%)

Comments: Research Models and Services (RMS) segment sales were flat at $172.3 million in the quarter, and $707.1 million for the year, up 2%. Preclinical Services (PCS) segment sales were $117.0 million in the quarter, up 8%, led by demand from mid-tier biotechnology clients, as well as continued growth of global key accounts, and for the year sales were $458.4 million, up 6%.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On